Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–89 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Shionogi Inc. Clear all
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00748852
View directory record Official record
Conditions
Dyslipidemia
Interventions
JTT-302
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03832738
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis, Skin Diseases
Interventions
JTE-451 Tablets, Placebo Tablets
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Santa Monica, California • Temecula, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 31, 2026, 1:48 PM EDT
Completed No phase listed Observational

Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

NCT04259255
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Edaravone (Radicava®/Radicava ORS®)
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 1:48 PM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT01129024
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Lusutrombopag
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

NCT01978587
View directory record Official record
Conditions
Anemia in Chronic Kidney Disease
Interventions
JTZ-951
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 31, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

NCT04355169
View directory record Official record
Conditions
Postoperative Gastrointestinal Dysfunction
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Tucson, Arizona • Louisville, Kentucky • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess S-309309 in Healthy and Obese Participants

NCT05247970
View directory record Official record
Conditions
Obesity
Interventions
S-309309, Midazolam, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

NCT07217886
View directory record Official record
Conditions
Renal Impairment
Interventions
S-892216-PO
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Orlando, Florida • St. Petersburg, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of S-600918 in Adults With Refractory Chronic Cough

NCT04110054
View directory record Official record
Conditions
Chronic Cough
Interventions
S-600918, Placebo to S-600918
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
51
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Tempe, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

Cefiderocol PK in Patients on ECMO

NCT04995835
View directory record Official record
Conditions
Sepsis
Interventions
Cefiderocol
Drug
Lead sponsor
Joseph L. Kuti, PharmD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Hartford, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 31, 2026, 1:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

NCT05101070
View directory record Official record
Conditions
Solid Tumors
Interventions
S-531011, Pembrolizumab, Bevacizumab
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 31, 2026, 1:48 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls

NCT07857837
View directory record Official record
Conditions
Renal Impairment
Interventions
Sulthiame
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Altamonte Springs, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects

NCT00788528
View directory record Official record
Conditions
Obesity
Interventions
S-2367 (velneperit)
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
73
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 31, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

NCT00997152
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
JTT-654, JTT-654 Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 31, 2026, 1:48 PM EDT